Vetoquinol: 2023 Calendar of Financial Communication

10 Jan 2023 20:00 CET

Regulatory News:

Vetoquinol (Paris:VETO) published its calendar of financial communication for 2023.

Next update: 2022 Annual revenues, January 18^th, 2023 after market close

ABOUT VETOQUINOL
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the farm animals (cattle and pigs) and pet (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group’s hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employed 2,621 people as of June 30^th, 2022.

Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).
The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005516/en/

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor & Media Relations
Emmanuel Dovergne
Tel.: +33 (0) 1 56 43 44 63
emmanuel.dovergne@keima.fr